11,479 Shares in Glaukos Corporation $GKOS Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in Glaukos Corporation (NYSE:GKOS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,479 shares of the medical instruments supplier’s stock, valued at approximately $936,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its holdings in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 136 shares during the period. AQR Capital Management LLC increased its position in Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after purchasing an additional 198 shares in the last quarter. Amalgamated Bank raised its holdings in Glaukos by 1.5% in the third quarter. Amalgamated Bank now owns 16,238 shares of the medical instruments supplier’s stock valued at $1,324,000 after buying an additional 242 shares during the period. Profund Advisors LLC raised its holdings in Glaukos by 13.9% in the second quarter. Profund Advisors LLC now owns 2,822 shares of the medical instruments supplier’s stock valued at $291,000 after buying an additional 345 shares during the period. Finally, California State Teachers Retirement System lifted its position in Glaukos by 0.8% during the second quarter. California State Teachers Retirement System now owns 50,854 shares of the medical instruments supplier’s stock valued at $5,253,000 after buying an additional 421 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GKOS. Wells Fargo & Company increased their price objective on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Piper Sandler reiterated an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a report on Wednesday, January 14th. Citigroup raised their price objective on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Stephens boosted their price objective on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, January 2nd. Finally, Stifel Nicolaus increased their target price on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $132.54.

Insider Activity at Glaukos

In other Glaukos news, Director Marc Stapley sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the transaction, the director directly owned 37,449 shares of the company’s stock, valued at $4,782,611.79. This represents a 28.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total transaction of $33,075.00. Following the sale, the chief financial officer directly owned 50,488 shares of the company’s stock, valued at $5,301,240. The trade was a 0.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 329,655 shares of company stock worth $37,752,234 over the last ninety days. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

NYSE:GKOS opened at $119.68 on Monday. The firm has a 50-day moving average of $113.22 and a two-hundred day moving average of $96.83. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The stock has a market cap of $6.87 billion, a P/E ratio of -77.72 and a beta of 0.70. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.78.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.